Want to see HK:2142 full AI Analyst Report?
HBM Holdings Ltd. (2142) AI Stock Analysis
HBM Holdings Ltd.
(HKEX:2142)
The score is supported by materially improved recent financial performance (profitability, growth, and cash generation), but is held back by weak technical momentum (below key moving averages with negative MACD and low RSI/Stoch). Valuation is reasonable at ~14.9x earnings but not compelling enough to offset the bearish technical backdrop and historical financial volatility.
HBM Holdings Ltd. (2142) vs. iShares MSCI Hong Kong ETF (EWH)
- Market Cap
- HKD 8.10B
- Dividend Yield
- ―
- Average Volume (3M)
- 9.59M
- Price to Earnings (P/E)
- 12.3
- Beta (1Y)
- 1.41
- Revenue Growth
- 55.31%
- EPS Growth
- 6.85%
- Country
- Hong Kong
- Employees
- 327
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
HBM Holdings Ltd. Business Overview & Revenue Model
Company Description
HBM Holdings Limited is a clinical-stage biopharmaceutical enterprise focused on identifying and developing unique antibody-based treatments for a variety of immunological conditions and cancers. The company's pipeline includes several promising asse...
HBM Holdings Ltd. Financial Statement Overview
Summary
Strong 2025 turnaround with sharply improved profitability (very high margins), rapid revenue growth, improving leverage, and positive operating/free cash flow. However, multi-year volatility in revenue, earnings, and cash flows (notably 2020–2024 swings) lowers confidence in the durability of the recent step-up.
Income Statement
78PositiveBalance Sheet
73PositiveCash Flow
66Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 178.96M | 158.21M | 38.10M | 89.50M | 40.66M | 4.31M |
| Gross Profit | 165.66M | 147.13M | 33.61M | 87.47M | 40.53M | 4.17M |
| EBITDA | 83.16M | 83.23M | -810.00K | 31.18M | -127.00M | -130.84M |
| Net Income | 84.38M | 91.47M | 2.78M | 22.80M | -137.27M | -137.88M |
Balance Sheet | ||||||
| Total Assets | 533.26M | 500.26M | 215.01M | 228.48M | 232.12M | 282.36M |
| Cash, Cash Equivalents and Short-Term Investments | 359.55M | 401.90M | 167.22M | 140.72M | 171.71M | 216.30M |
| Total Debt | 89.70M | 81.77M | 61.34M | 66.01M | 90.93M | 19.47M |
| Total Liabilities | 115.51M | 133.14M | 90.96M | 108.85M | 139.62M | 59.45M |
| Stockholders Equity | 417.80M | 367.13M | 124.45M | 119.99M | 92.83M | 223.19M |
Cash Flow | ||||||
| Free Cash Flow | 6.67M | 69.58M | 30.44M | -21.60M | -118.40M | -139.81M |
| Operating Cash Flow | 13.85M | 81.33M | 30.68M | -19.12M | -99.96M | -125.61M |
| Investing Cash Flow | -252.51M | -179.02M | 6.55M | 28.09M | 137.59M | -76.90M |
| Financing Cash Flow | 54.25M | 157.35M | -10.24M | -29.14M | 70.58M | 1.59M |
HBM Holdings Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2142, the sentiment is Negative. The current price of 9.76 is below the 20-day moving average (MA) of 10.96, below the 50-day MA of 13.08, and below the 200-day MA of 12.55, indicating a bearish trend. The MACD of -0.94 indicates Positive momentum. The RSI at 31.83 is Neutral, neither overbought nor oversold. The STOCH value of 22.64 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2142.
HBM Holdings Ltd. Peers Comparison
Overall Rating
HK:195262Neutral- HK:214261Neutral
HK:215753Neutral
HK:996652Neutral
HK:261646.6Neutral
HK:217139Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| HK:1952 | 62Neutral | HKD 9.58B | -145.11 | -1.02% | ― | 192.64% | 92.31% |
| HK:2142 | 61Neutral | HKD 8.72B | 12.32 | 21.50% | ― | 55.31% | 6.85% |
| HK:2157 | 53Neutral | HKD 5.69B | 19.79 | 17.36% | ― | 46.90% | ― |
| HK:9966 | 52Neutral | HKD 6.06B | -30.68 | -10.27% | ― | -31.77% | -177.01% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| HK:2616 | 47Neutral | HKD 7.77B | -15.53 | -43.54% | ― | 116.67% | -0.42% |
| HK:2171 | 39Underperform | HKD 6.32B | -56.08 | -9.45% | ― | 68.12% | 81.84% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HK:2142 | HBM Holdings Ltd. | 9.76 | -3.92 | -28.69% | |
| HK:9966 | Alphamab Oncology | 6.21 | -5.46 | -46.79% | |
| HK:1952 | Everest Medicines Ltd. | 27.02 | -22.34 | -45.26% | |
| HK:2157 | Lepu Biopharma Co. Ltd. Class H | 3.15 | -3.23 | -50.55% | |
| HK:2171 | CARsgen Therapeutics Holdings Ltd. | 10.63 | -6.92 | -39.43% | |
| HK:2616 | CStone Pharmaceuticals | 4.94 | -1.28 | -20.58% |
HBM Holdings Ltd. Corporate Events
HBM Holdings Wins NMPA Approval for First FcRn Biologic in China
HBM Holdings Ltd., a Hong Kong-listed biotech developer of autoimmune disease therapies, has advanced its core product batoclimab through a partnership-driven model that combines upstream R&D with downstream licensing. Its commercialization strat...
HBM Holdings Sets Commercial Path for Core Myasthenia Drug in Greater China
HBM Holdings Ltd., a Cayman-incorporated biopharmaceutical group listed in Hong Kong, is focused on antibody-based therapies for autoimmune and neurological diseases. Its strategy relies on core products under the Chapter 18A framework and regional l...
HBM’s Nona Biosciences Unveils AI Model for Fully Human Heavy-Chain-Only Antibodies
HBM Holdings Limited has announced that its wholly owned subsidiary Nona Biosciences has developed HCAbLM, described as the world’s first language model specifically trained on fully human heavy-chain-only antibodies. Built on a large repertoir...
HBM Holdings Partner Solstice Oncology Secures US$225 Million Series A for Neoadjuvant Immunotherapy Push
HBM Holdings Ltd. reported that its partner Solstice Oncology has launched with a US$225 million Series A financing round led by RA Capital Management, with participation from Canaan Partners, Forbion and other investors. Solstice is a clinical-stage...
HBM Holdings Advances Long-Acting Asthma Antibody After Positive Phase II Data
HBM Holdings Ltd. reported that its partner Windward Bio has delivered positive interim Phase II data from the POLARIS-1 trial of HBM9378/WIN378, a fully human, ultra-long-acting monoclonal antibody targeting TSLP in adults with uncontrolled asthma....
HBM Holdings Shares Added to Shanghai and Shenzhen Stock Connect
HBM Holdings Ltd. announced that its shares will be included in both the Shanghai–Hong Kong Stock Connect and the Shenzhen–Hong Kong Stock Connect programs, effective 7 September 2026. The move allows qualified Mainland Chinese investors...
HBM Holdings Clarifies Executive Director Resignation and Confirms Board Changes
HBM Holdings Limited has issued a supplemental announcement clarifying the circumstances surrounding a recent leadership reshuffle, including the resignation of executive director Dr. Yiping Rong and the appointment of new executive directors and an...
HBM Holdings Reshapes Board With Executive Changes and New Appointments
HBM Holdings announced that executive director Dr. Yiping Rong will resign effective 27 August 2026 for personal reasons, with the board noting there is no disagreement and expressing appreciation for his contributions. The move signals an orderly le...
HBM Holdings Clarifies Board Composition and Governance Structure
HBM Holdings Ltd., incorporated in the Cayman Islands and listed in Hong Kong under stock code 02142, is governed by a board comprising executive and independent non-executive directors. The company is led by Chief Executive Officer and Chairman Dr....
HBM Holdings Boosts Revenue and Advances Biologics Pipeline Amid Higher R&D Spend
HBM Holdings reported interim unaudited revenue of US$122.5 million for the six months ended 30 June 2026, up from US$101.3 million a year earlier, while profit for the period slipped to US$64.9 million from US$73.0 million as research and developmen...
HBM Holdings to Join Hang Seng Composite Index, Aiming to Boost Liquidity and Investor Reach
HBM Holdings Limited announced that it will be included as a constituent of the Hang Seng Composite Index, with the change taking effect on 7 September 2026. This index inclusion is expected to qualify the company’s shares for trading under the...
HBM Holdings Wins China IND Nod for Novel Cancer Antibody HBM7004
HBM Holdings Ltd. has secured National Medical Products Administration approval in China for the investigational new drug application of HBM7004, a novel B7H4xCD3 bispecific antibody for advanced solid tumors. This clearance complements previously ob...
HBM Holdings Sets August Board Meeting to Approve Interim Results
HBM Holdings Limited has scheduled a board meeting for 27 August 2026 to review and approve the group’s interim results for the six months ended 30 June 2026. The meeting will also address other board business, signaling routine corporate gover...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 09, 2026